Evidence map›Paper›PMID 40346687›Full record

ArticleActa neuropathologica communications2025

Altered CD4 T cell response in oligometatastic non-small cell lung cancer brain metastasis.

Mais Alsousli, Cecile L Maire, Andras Piffko, Jakob Matschke, Laura Glau, Merle Reetz, Svenja Schneegans, Gresa Emurlai, Benedikt Asey, Alessandra Rünger and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Value of a BRAFFrontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mais AlsousliDepartment of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Cecile L MaireDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andras PiffkoDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jakob MatschkeInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Laura GlauInstitute of Immunology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Merle ReetzDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Svenja SchneegansDepartment of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Gresa EmurlaiDepartment of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Benedikt AseyDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alessandra RüngerDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sven PeineInstitute of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jolanthe KropidlowskiDepartment of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Jens GemptDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Markus GlatzelInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Manfred WestphalDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eva TolosaInstitute of Immunology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Katrin LamszusDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Klaus PantelDepartment of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Simon A JoosseDepartment of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Malte Mohme *Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Harriet Wikman *Department of Tumor Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany. h.wikman@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer mortality globally, with brain metastasis (BM) in 40% of advanced non-small-cell lung cancer (NSCLC) cases. In 15% of these cases, the brain is the sole affected organ (oligometastasis), which correlates with a better prognosis compared to widespread disease. It remains unclear if brain-only metastasis without systemic spread is due to the immune system's ability to control systemic tumor progression. We studied the immune cell compositions in NSCLC patients with BM, identifying novel patterns associated with BM, and specifcally with either oligo- or polymetastatic spread. Multi-parametric immune phenotyping of peripheral blood primarily showed alterations in the CD4

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungCD4-Positive T-LymphocytesLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedTumor MicroenvironmentBrain metastasisCD4ImmunophenotypingNSCLCT cells

Identifiers

PMID40346687
PMCPMC12063345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.